Presentation addressed metabolomics, focusing on small molecule metabolites that are proximal effectors of health and disease and hold promise in many aspects of drug development and personal medicine
Lipomics Technologies, a privately held company that develops tools for assessing and understanding complex metabolic processes using proprietary technologies for lipid metabolite analysis and interpretation, reports that Steve Watkins, Lipomics founder, president, and chief scientific officer, was a guest speaker at the recent Genomics and Proteomics Interest Group meeting at the Food and Drug Administration (FDA).
Watkins's presentation addressed metabolomics, perhaps the youngest of the '-omics' sciences, focusing on small molecule metabolites that are proximal effectors of health and disease and hold considerable promise in many aspects of drug development and personalised medicine.
"The FDA is clearly thinking to the future by devoting a session of a group generally focused on genomics to the topic of metabolomics" said Tom Anderson, Lipomics's CEO.
"The FDA is looking ahead to applications of metabolomics in the drug development process and we are pleased that Steve was asked to provide the overview to this group".
Chaired by Norris Alderson, the associate commissioner of science at the FDA, this working group includes leading scientists at each of the seven centres of the FDA.
The group meets periodically to enable FDA scientific leaders to stay current with the rapidly changing landscape of genomics and proteomics.
Lipomics Technologies provides metabolic profiling for drug discovery and development, patient monitoring and personalised medicine.
The company's proprietary analytical technologies generate a comprehensive, accurate and quantitative profile of lipid metabolites.
A broad range of bioinformatics and analytical tools map these profiles to activity levels of underlying biochemical pathways.
Through these tools, new insights are gained into biological and metabolic changes induced by disease, drug action, nutritional or lifestyle influences.
In partnership with pharmaceutical, biotechnology and nutrition companies, Lipomics uses its technologies to discover new biomarkers, speed drug discovery, improve clinical trial stratification, reduce late-stage drug attrition, develop early tests for monitoring drug response and enable individualised health management.
